Related Experiment Videos
Evaluation of a "nude" mouse-human tumor panel as a predictive secondary screen for cancer chemotherapeutic agents
Abstract:
Nine established human melanoma tissue-cultured cell lines heterotransplanted in C57BL/6 "nude" mice were exposed to each of 4 chemotherapeutic agents of known clinical activity against human melanoma. Two of the therapeutic agents, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 5-(3,3-dimethyl-1-triazino) imidazole-4-carboxamide (DTIC), are known to be active against human melanoma; the other two, adriamycin and 5-azacytidine, are known to be inactive. Sterile saline served as a control agent. In 2 cell line heterotransplants, the control tumor spontaneously regressed. Of the 7 cell lines that remained for evaluation, 4 were sensitive to DTIC, 1 was sensitive to BCNU, and none was sensitive to adriamycin or 5-azacytidine. These data indicate that the nude mouse-human tumor model may be a predictive secondary screen for cancer chemotherapeutic agents.
Insights
The nude mouse-human tumor model effectively screened chemotherapy drugs for melanoma. This model showed sensitivity to DTIC and BCNU, but not adriamycin or 5-azacytidine, suggesting its predictive value.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Human melanoma cell lines were utilized to establish a xenograft model in nude mice.
- The model aimed to assess the efficacy of chemotherapeutic agents against human melanoma.
Purpose of the Study:
- To evaluate the predictive capability of the nude mouse-human tumor model as a secondary screen for anticancer agents.
- To determine the sensitivity of human melanoma xenografts to specific chemotherapeutic drugs.
Main Methods:
- Nine human melanoma cell lines were heterotransplanted into C57BL/6 nude mice.
- Tumors were treated with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 5-(3,3-dimethyl-1-triazino) imidazole-4-carboxamide (DTIC), adriamycin, 5-azacytidine, or saline control.
- Tumor response was evaluated based on sensitivity to the agents.
Main Results:
- Two of the seven evaluable xenotransplants showed spontaneous regression in the control group.
- Four cell lines demonstrated sensitivity to DTIC, and one cell line was sensitive to BCNU.
- No sensitivity was observed for adriamycin or 5-azacytidine against the tested melanoma xenografts.
Conclusions:
- The nude mouse-human tumor model demonstrated potential as a predictive secondary screening tool for chemotherapeutic agents.
- The model successfully identified differential drug sensitivities, aligning with known clinical activity for DTIC and BCNU.
- This xenograft model may aid in the preclinical evaluation of novel melanoma therapies.